
This issue of the SFARI newsletter includes: (1) SFARI 2020 Research awardees, (2) SFARI’s response to appeals for racial justice in science and society, (3) SPARK update: New phenotypic data now available, (4) SFARI Gene: New data release, (5) Requesting SFARI data and biospecimens during COVID-19 pandemic, (6) SFARI abstracts and e-posters at INSAR 2020 Virtual, (7) SFARI Investigator and board member elected to the National Academy of Sciences, (8) SFARI Investigators and board member elected to the American Academy of Arts & Sciences, (9) Workshop report: SFARI workshop explores challenges and opportunities of gene therapies for autism spectrum disorder, (10) Highlights of SFARI-funded research, (11) Past webinar: Allyson Berent, “From parent advocate to nonprofit chief science officer, to biotherapeutic company cofounder — A personal journey through drug development for Angelman syndrome.”

SFARI would like to remind researchers that they can still request many SFARI resources, including genetic and phenotypic data as well as biospecimens, at this time. Researchers can also submit applications to recruit individuals with autism and their families for new research studies.

On February 6–7, 2020, SFARI convened a two-day workshop to explore the possibility of gene therapies for autism spectrum disorder.

New data were added to SFARI Gene in April 2020. This data release included the addition of new candidate autism risk genes, new curated references of copy number variations associated with autism, as well as updated gene scoring criteria. New mouse models derived from notable autism risk genes were also added.

Benjamin Neale discussed progress in mapping genetic risk factors for autism, schizophrenia and bipolar disorder.
- Previous Page
- Viewing
- Next Page